Glypican 4 may be involved in the adipose tissue redistribution in high‑fat feeding C57BL/6J mice with peroxisome proliferators‑activated receptor γ agonist rosiglitazone treatment

Liu,Li; Gu,Hailun; Zhao,Yue; An,Li; Yang,Jun

doi:10.3892/etm.2014.1998

Glypican 4 may be involved in the adipose tissue redistribution in high‑fat feeding C57BL/6J mice with peroxisome proliferators‑activated receptor γ agonist rosiglitazone treatment

Authors:
- Li Liu
- Hailun Gu
- Yue Zhao
- Li An
- Jun Yang
View Affiliations

Affiliations: Department of Nutrition and Food Hygiene, School of Public Health, China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Orthopedics, Shengjing Hospital, China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: September 30, 2014 https://doi.org/10.3892/etm.2014.1998
Pages: 1813-1818

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fat distribution affects the risk of developing obesity‑related chronic diseases. Glypican 4 (Gpc4) may be involved in the regulation of obesity and body fat distribution. The aim of the study was to explore whether Gpc4 affects fat accumulation and the possible mechanism. C57BL/6J mice were fed with a high‑fat diet for eight weeks and treated with a peroxisome proliferators‑activated receptor γ (PPARγ) agonist, rosiglitazone, for another four weeks. The weight of inguinal and epididymal fat pads was determined. The Gpc4 mRNA and protein expression and two probable regulators of the Gpc4 gene, specificity protein 1 (Sp1) and Sp3 mRNA, were also measured. Mice treated with rosiglitazone showed a significant increase in subcutaneous fat weight compared with the untreated mice. The expression of Gpc4 mRNA and protein was significantly higher in visceral than in subcutaneous fat in all the groups. Compared with untreated mice the expression of Gpc4 and Sp3 mRNA in subcutaneous fat and the expression of Sp1 and Sp3 mRNA in visceral fat in mice treated with rosiglitazone increased significantly. The Sp3/Sp1 ratio was consistent with the expression of Gpc4 mRNA and protein in subcutaneous and visceral fat. The present study indicated that Gpc4 may play an important role in fat distribution, and this effect is perhaps regulated by the ratio of Sp3/Sp1 in the subcutaneous and visceral fat tissues.

View Figures

View References

1	Pischon T, Boeing H, Hoffmann K, et al: General and abdominal adiposity and risk of death in Europe. N Engl J Med. 359:2105–2120. 2008. View Article : Google Scholar : PubMed/NCBI
2	Tumova S, Woods A and Couchman JR: Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int J Biochem Cell Biol. 32:269–288. 2000. View Article : Google Scholar : PubMed/NCBI
3	Fico A, Maina F and Dono R: Fine-tuning of cell signaling by glypicans. Cell Mol Life Sci. 68:923–929. 2011. View Article : Google Scholar : PubMed/NCBI
4	Li H, Melford K, Judson A and Bensadoun A: Murine glypican-4 gene structure and expression; Sp1 and Sp3 play a major role in glypican-4 expression in 3T3-F442A cells. Biochim Biophys Acta. 1679:141–155. 2004. View Article : Google Scholar : PubMed/NCBI
5	Gesta S, Blüher M, Yamamoto Y, et al: Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci USA. 103:6676–6681. 2006. View Article : Google Scholar : PubMed/NCBI
6	Liu L, Liu HM, Gu HL, et al: Effect of low dose di-2-ethylhexylphthalate exposure on fat distribution of offspring mice in pregnant mice. J Southeast Univ (Med Sci Edi). 33:147–150. 2014.(In Chinese).
7	Smith SR, De Jonge L, Volaufova J, et al: Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism. 54:24–32. 2005. View Article : Google Scholar : PubMed/NCBI
8	Adams M, Montague CT, Prins JB, et al: Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest. 100:3149–3153. 1997. View Article : Google Scholar
9	Kang JG, Park CY, Ihm SH, et al: Mechanisms of adipose tissue redistribution with rosiglitazone treatment in various adipose depots. Metabolism. 59:46–53. 2010. View Article : Google Scholar : PubMed/NCBI
10	Laplante M, Festuccia WT, Soucy G, et al: Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism. Diabetes. 55:2771–2778. 2006. View Article : Google Scholar
11	Laplante M, Sell H, MacNaul KL, et al: PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes. 52:291–299. 2003. View Article : Google Scholar
12	Ma LJ, Mao SL, Taylor KL, et al: Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes. 53:336–346. 2004. View Article : Google Scholar : PubMed/NCBI
13	Kuda O, Stankova B, Tvrzicka E, et al: Prominent role of liver in elevated plasma palmitoleate levels in response to rosiglitazone in mice fed high-fat diet. J Physiol Pharmacol. 60:135–140. 2009.PubMed/NCBI
14	Liu L, Gu H, Yang J, et al: Adipogenic differentiation is not influenced by lentivirus-mediated shRNA targeting the SOCS3 gene in adipose-derived stromal cells. Mol Biol Rep. 37:2455–2462. 2010. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
16	Scion image software version 4.0. http://www.bbioo.com/download/58-196-1.htmluri. Accessed March 26, 2008
17	Hsu WH, Lee BH, Hsu YW and Pan TM: Peroxisome proliferator-activated receptor-γ activators monascin and rosiglitazone attenuate carboxymethyllysine-induced fibrosis in hepatic stellate cells through regulating the oxidative stress pathway but independent of the receptor for advanced glycation end products signaling. J Agric Food Chem. 61:6873–6879. 2013.
18	Chappard D, Marchand-Libouban H, Moreau MF and Baslé MF: Thiazolidinediones cause compaction of nuclear heterochromatin in the pluripotent mesenchymal cell line C3H10T1/2 when inducing an adipogenic phenotype. Anal Quant Cytopathol Histopathol. 35:85–94. 2013.PubMed/NCBI
19	Day C: Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med. 16:179–192. 1999. View Article : Google Scholar : PubMed/NCBI
20	Fonseca V: Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med. 115 Suppl 8A:42S–48S. 2003. View Article : Google Scholar : PubMed/NCBI
21	Takasawa K, Kubota N, Terauchi Y and Kadowaki T: Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment. Endocr J. 55:767–776. 2008. View Article : Google Scholar : PubMed/NCBI
22	van Harmelen V, Dicker A, Rydén M, et al: Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes. 51:2029–2036. 2002.PubMed/NCBI
23	Ussar S, Bezy O, Blüher M and Kahn CR: Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine. Diabetes. 61:2289–2298. 2012. View Article : Google Scholar : PubMed/NCBI
24	Yoo HJ, Hwang SY, Cho GJ, et al: Association of glypican-4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 98:2897–2901. 2013. View Article : Google Scholar : PubMed/NCBI
25	Sassa Y, Hata Y, Aiello LP, et al: Bifunctional properties of peroxisome proliferator-activated receptor gamma1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3. Diabetes. 53:1222–1229. 2004. View Article : Google Scholar : PubMed/NCBI
26	Sugawara A, Uruno A, Kudo M, et al: Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells. J Biol Chem. 277:9676–9683. 2002. View Article : Google Scholar
27	Chung SS, Choi HH, Cho YM, Lee HK and Park KS: Sp1 mediates repression of the resistin gene by PPARgamma agonists in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 348:253–258. 2006. View Article : Google Scholar : PubMed/NCBI
28	Chung SS, Kim JH, Park HS, et al: Activation of PPARgamma negatively regulates O-GlcNAcylation of Sp1. Biochem Biophys Res Commun. 372:713–718. 2008. View Article : Google Scholar : PubMed/NCBI